<div id="readability-page-1"><div><p>Natera, Inc. announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with stage III colorectal cancer (CRC).</p><p>The pre-specified post-hoc analysis included 940 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX +/- celecoxib, a non-steroidal anti-inflammatory drug (NSAID). Key findings included: Adding celecoxib to conventional chemotherapy in Signatera-positive patients, after surgery reduced the risk of cancer recurrence and death by ~40%. Celecoxib improved disease-free survival (DFS) (adjusted HR=0.61, 95% CI 0.42-0.89; 3-year 41.0% vs.</p><p>22.6%) and overall survival (OS) (adjusted HR=0.,62, 95% CI 0.40-0.96; 5-year: 61.6% vs. 39.9%) compared to placebo in Signatera-positive patient. Celecoxib benefit in Signatera-positive Patients was independent of demographic, pathologic or molecular factors, including PIK3CA status, further defining a patient population who may benefit from the addition to adjvant treatment.</p><p>Celecoxib improved DFS of Signatera-positive patients for both PIK3CA wild-type (adjusted HR=0.64, 95% CI 0. 42-0.98) and PIK3CA altered (adjusted HR=0.19, 95% CI 0.06-0.58) tumors.</p></div></div>

NTRA

<p>Natera, Inc. 宣布在《JAMA Oncology》上发表了 CALGB/SWOG 80702 研究的结果，显示在 Signatera 阳性的结直肠癌患者中，添加塞来昔布到化疗中可将复发和死亡风险降低约 40%。塞来昔布改善了无病生存期和总体生存期，与人口统计学或分子因素（包括 PIK3CA 状态）无关</p>

Natera 公司宣布在结直肠癌的随机 III 期 CALGB/SWOG 80702 研究中发表 Signatera 分析结果